Experimental Injectable Drug Pemvidutide Shows Promise in Reducing Heavy Drinking Days for Alcohol Use Disorder

July 29, 2026

In a novel development at the intersection of metabolic science and addiction medicine, an experimental once-weekly injectable medication originally designed for obesity and liver disease has demonstrated significant efficacy in curbing severe drinking habits among adults with alcohol use disorder (AUD).

Biopharmaceutical company Altimmune announced Tuesday that its lead drug candidate, pemvidutide, successfully met its primary endpoint in the Phase 2 RECLAIM clinical trial. Over a 24-week period, the therapy yielded a statistically significant reduction in heavy drinking days compared to a placebo among adults diagnosed with moderate to severe AUD alongside co-occurring overweight status or obesity.

These mid-stage findings add momentum to a growing body of medical research evaluating whether weight-loss and diabetes drugs—specifically those targeting gut-brain hormone pathways—can successfully rewire the brain’s reward circuits to treat substance use disorders.

Dual-Action Approach: How Pemvidutide Works

Pemvidutide belongs to an emerging class of metabolic therapies, but with a structural twist. While popular medications like semaglutide (Ozempic, Wegovy) target a single hormone receptor called GLP-1 (glucagon-like peptide-1), pemvidutide is a balanced dual receptor agonist. It simultaneously activates two distinct chemical pathways in the body:

• GLP-1 Receptors: Found in the gut and brain, activation of these receptors slows digestion, promotes satiety (feeling full), and regulates brain reward pathways that govern cravings.

• Glucagon Receptors: Primarily active in the liver, these receptors stimulate fat burning and energy expenditure, directly targeting liver fat accumulation, inflammation, and cellular damage (fibrosis).

Originally developed to address metabolic dysfunction-associated steatohepatitis (MASH), alcohol-associated liver disease (ALD), and obesity, pemvidutide’s ability to reduce alcohol consumption appears to leverage GLP-1’s capacity to dull the neurochemical “reward” signal associated with drinking.

Key Clinical Trial Findings

The randomized, placebo-controlled RECLAIM trial evaluated approximately 100 men and women diagnosed with both AUD and a body mass index (BMI) in the overweight or obese range. At baseline, participants reported heavy alcohol consumption, averaging at least 28 drinks per week for men and 21 drinks per week for women.

Defining a Heavy Drinking Day: According to health standards, a “heavy drinking day” is defined as consuming five or more standard drinks for men, or four or more for women, within a single period.

Over 24 weeks, the trial recorded several clear clinical outcomes:

• Fewer Heavy Drinking Days: Participants receiving a weekly 2.4 mg injection of pemvidutide reduced their heavy drinking days by an average of 4.2 days per week, compared to a 2.75-day reduction in the placebo group (a placebo-adjusted net reduction of 1.45 days per week).

• Achieving Sustained Abstinence from Heavy Drinking: Notably, 42.2% of participants in the pemvidutide arm achieved zero heavy drinking days during the final four weeks of treatment—more than double the rate observed in the placebo arm.

• Improved Drinking Risk Categories: Nearly two-thirds (65%) of pemvidutide-treated patients achieved a two-level reduction in World Health Organization Risk Drinking Levels (WHO-RDL), a standard clinical metric used to evaluate meaningful risk reduction in AUD patients.

• Biological & Metabolic Proof: Patients in the treatment group showed a marked increase in total abstinence days alongside decreased levels of phosphatidylethanol (PEth)—a direct blood biomarker used to objectively verify reduced alcohol intake. Additionally, treated patients experienced a statistically significant 9.1% placebo-adjusted reduction in total body weight at week 24.

“We are extremely encouraged by these compelling topline results, which showed a highly significant reduction in heavy drinking days and nearly two-thirds of patients treated with pemvidutide achieving a two-level reduction in their WHO-RDL, a clinically meaningful outcome for these patients,” stated Dr. Christophe Arbet-Engels, Chief Medical Officer at Altimmune, in a company release.

Addressing an Unmet Need in Addiction Medicine

Alcohol use disorder remains a public health crisis. According to data from the National Institute on Alcohol Abuse and Alcoholism (NIAAA), approximately 29.5 million Americans aged 12 and older met the criteria for AUD in 2023.

While the U.S. Food and Drug Administration (FDA) has approved three medications to treat AUD—naltrexone, acamprosate, and disulfiram—they remain vastly underutilized due to variable patient response, gastrointestinal side effects, and strict daily dosing regimens that challenge long-term adherence.

A once-weekly injection that simultaneously targets alcohol cravings, metabolic health, and weight management could bridge a critical gap, particularly for individuals living with both AUD and metabolic conditions like fatty liver disease or cardiovascular risk.

Safety Profile and Trial Limitations

Throughout the 24-week evaluation, pemvidutide demonstrated a generally favorable safety profile. The vast majority of reported side effects were gastrointestinal in nature and mild to moderate in severity.

However, safety monitoring flagged one serious adverse event involving hyponatremia (abnormally low blood sodium levels) in the pemvidutide group, which the principal investigator noted as potentially related to the trial medication. Altimmune reported that overall safety data support advancing the drug to further stages of development.

Independent medical experts emphasize that while these findings are promising, they must be interpreted within the context of early-stage clinical research:

• Sample Size: The study enrolled roughly 100 participants, a relatively small cohort that necessitates validation in larger trials.

• Specific Patient Population: All participants were overweight or obese, meaning researchers cannot yet assume the drug will act identically in individuals with AUD who maintain a normal body mass index.

• Duration: A 24-week window offers valuable short-term data, but chronic conditions like AUD require evaluating long-term safety, relapse rates, and durability of treatment over several years.

Next Steps for Development

Altimmune has announced plans to request an End-of-Phase 2 (EOP2) meeting with the FDA to map out the regulatory pathway forward and design Phase 3 clinical trials.

If future pivotal trials confirm these mid-stage results, pemvidutide could become one of the first dual-receptor metabolic therapies approved for addiction medicine—offering a much-needed tool for patients seeking to regain control over their health.

Medical Disclaimer

Medical Disclaimer: This article is for informational purposes only and should not be considered medical advice. Always consult with qualified healthcare professionals before making any health-related decisions or changes to your treatment plan. The information presented here is based on current research and expert opinions, which may evolve as new evidence emerges.

References

1. Reuters. “Altimmune’s drug meets main goal of mid-stage study for alcohol use disorder.” Published July 28, 2026. https://www.reuters.com/business/healthcare-pharmaceuticals/altimmunes-drug-meets-main-goal-mid-stage-study-alcohol-use-disorder-2026-07-28/